1-(4-bromo-2-chlorophenyl)piperazine | 944662-98-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(4-bromo-2-chlorophenyl)piperazine
• CAS: 944662-98-0
• 化学式: C₁₀H₁₂BrClN₂
• 分子量: 275.576
• InChiKey: OTSXMQBXKSBTJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-bromo-2-chlorophenyl)piperazine 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium acetate 、 三乙酰氧基硼氢化钠 作用下， 以 二氧六环-d8 、 二氯甲烷 为溶剂， 反应 40.0h， 生成 1-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-4-ethylpiperazine
  参考文献：
  名称：

  PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF

  摘要：

  揭示了Formula (I)的化合物，使用这些化合物抑制ALK2活性和/或FGFR活性的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或改善与ALK2活性和/或FGFR活性相关的疾病或疾病方面具有用处，如癌症。

  公开号：

  US20200095250A1

文献信息

• Pyrazolopyrimidine compounds and uses thereof
  申请人：Incyte Corporation

  公开号：US11111247B2

  公开（公告）日：2021-09-07

  Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and/or FGFR activity, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity and/or FGFR activity, such as cancer.

  本发明公开了式(I)化合物、使用该化合物抑制ALK2活性和/或FGFR活性的方法，以及包含该化合物的药物组合物。这些化合物可用于治疗、预防或改善与 ALK2 活性和/或 FGFR 活性相关的疾病或紊乱，如癌症。
• PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 ABD/OR FGFR MODULATORS
  申请人：Incyte Corporation

  公开号：EP3856348A1

  公开（公告）日：2021-08-04
• [EN] PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 ABD/OR FGFR MODULATORS<br/>[FR] COMPOSÉS PYRAZOLO[4,3-D]PYRIMIDINE EN TANT QUE MODULATEURS DES ALK2 ET/OU FGFR
  申请人：INCYTE CORP

  公开号：WO2020068729A1

  公开（公告）日：2020-04-02

  Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and/or FGFR activity, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity and/or FGFR activity, such as cancer.
• SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF
  申请人：[en]ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA

  公开号：WO2023250082A2

  公开（公告）日：2023-12-28

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecule compounds having a 6,6-heterocyclic structure (e.g., compounds having a naphthyridine, pyrido-pyridazine, pyrido-pyrazine, quinoline, pyrazino-pyridazine, pyrimido-pyrimidine, quinazoline, quinoxaline or cinnoline ring system) which function as inhibitors of DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK3, CLK4, CDK7, CDK8/19, PI3K, PDGFrA/B, mTOR, WNT, homeodomain-interacting kinases (HIPKs), and/or CMGC kinases leading to inhibition of WNT signaling, and their use as therapeutics for the treatment of Alzheimer's disease, down syndrome, Parkinson's disease, Huntington's disease, diabetes, autoimmune diseases, inflammatory disorders (e.g., airway inflammation, osteoarthritis (e.g., knee related osteoarthritis)), cancer (e.g., glioblastoma, prostate cancer, metastatic breast cancer, metastatic lung cancer, multiple myeloma, secondary metastatic tumors of the brain, colorectal cancer and metastatic colorectal cancer (e.g., metastatic colorectal cancer in the liver)), and other diseases.
• PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF
  申请人：Incyte Corporation

  公开号：US20200095250A1

  公开（公告）日：2020-03-26

  Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and/or FGFR activity, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity and/or FGFR activity, such as cancer.

  揭示了Formula (I)的化合物，使用这些化合物抑制ALK2活性和/或FGFR活性的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或改善与ALK2活性和/或FGFR活性相关的疾病或疾病方面具有用处，如癌症。